<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; groups</title>
	<atom:link href="http://www.tapanray.in/tag/groups/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Reaping Rich Harvest With Orphan Drugs</title>
		<link>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reaping-rich-harvest-with-orphan-drugs</link>
		<comments>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/#comments</comments>
		<pubDate>Mon, 21 Oct 2019 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[health for all]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[quid pro quo]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reaping]]></category>
		<category><![CDATA[rich harvest]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9752</guid>
		<description><![CDATA[A set of perplexing questions on the drug industry has been haunting many, since long. One such area is intimately associated with the core purpose of this business, as enunciated by each company, often publicly. Just to give a feel &#8230; <a href="http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma’s Perception Management</title>
		<link>http://www.tapanray.in/pharmas-perception-management/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmas-perception-management</link>
		<comments>http://www.tapanray.in/pharmas-perception-management/#comments</comments>
		<pubDate>Mon, 23 Sep 2019 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[Bono]]></category>
		<category><![CDATA[designing]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expenses. expenditure]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[Gallup]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[input]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[output]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Policies]]></category>
		<category><![CDATA[Poll]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9721</guid>
		<description><![CDATA[An intriguing input-output relationship in the pharma industry has remained baffling, since the last several years, where increasing financial inputs are resulting in diminishing productivity output. More disturbing is, this input-output relationship has now reached a new low, with their &#8230; <a href="http://www.tapanray.in/pharmas-perception-management/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmas-perception-management/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patient Services Aren’t Optional Any More For Pharma Business Excellence</title>
		<link>http://www.tapanray.in/patient-services-arent-optional-any-more-for-pharma-business-excellence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patient-services-arent-optional-any-more-for-pharma-business-excellence</link>
		<comments>http://www.tapanray.in/patient-services-arent-optional-any-more-for-pharma-business-excellence/#comments</comments>
		<pubDate>Mon, 20 Mar 2017 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[biotechnology]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[centered]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[conflict]]></category>
		<category><![CDATA[device]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[optional]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Pao]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[providers]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8140</guid>
		<description><![CDATA[In the modern world of abundance of information through various sources and platforms, patients are increasingly looking for greater engagement in their healthcare decision-making process with the doctors, slowly but steadily, and in that process seeking better services from different &#8230; <a href="http://www.tapanray.in/patient-services-arent-optional-any-more-for-pharma-business-excellence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patient-services-arent-optional-any-more-for-pharma-business-excellence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Awaiting ‘The Moment of Truth’ on ‘Working of Patents’ in India</title>
		<link>http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=awaiting-the-moment-of-truth-on-working-of-patents-in-india</link>
		<comments>http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/#comments</comments>
		<pubDate>Mon, 03 Nov 2014 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[Form 27]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[Indacaterol]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[inventive]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Onbrez]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Section 66]]></category>
		<category><![CDATA[Section 92]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[truth]]></category>
		<category><![CDATA[Unibrez Rotacaps]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6148</guid>
		<description><![CDATA[By a letter dated October 21, 2014 addressed to the Secretary, Department of Industrial Policy and Promotion (DIPP) of India, the domestic pharma major Cipla has sought for the revocation of five patents of Novartis AG’s respiratory drug Indacaterol (Onbrez) in India, &#8230; <a href="http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
